Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie

2026-04-05 18:13:20

Abstract generation in progress

DelveInsight’s report highlights a robust pipeline for Atopic Dermatitis, with over 100 companies developing more than 120 therapies. Recent FDA approvals and ongoing clinical trials signal significant advancements, including new topical and injectable options, and promising oral small molecules. Key companies like Pfizer, Kymera Therapeutics, and AstraZeneca are actively involved in developing innovative treatments to address the unmet needs in the Atopic Dermatitis market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.